Bruce Montgomery

Summary

Affiliation: University of Washington
Country: USA

Publications

  1. ncbi request reprint Expression of oncogenic epidermal growth factor receptor family kinases induces paclitaxel resistance and alters beta-tubulin isotype expression
    R B Montgomery
    Department of Medicine and Oncology, Veterans Affairs Puget Sound Health Care System, University of Washington, Seattle, Washington 98108, USA
    J Biol Chem 275:17358-63. 2000
  2. pmc Estradiol suppresses tissue androgens and prostate cancer growth in castration resistant prostate cancer
    Bruce Montgomery
    Department of Medicine, University of Washington School of Medicine, 1959 NE Pacific St, Seattle, WA, USA
    BMC Cancer 10:244. 2010
  3. doi request reprint Veterans Affairs Cooperative Studies Program study 553: Chemotherapy after prostatectomy, a phase III randomized study of prostatectomy versus prostatectomy with adjuvant docetaxel for patients with high-risk, localized prostate cancer
    Bruce Montgomery
    Veterans Affairs Puget Sound Health Care System and University of Washington, Seattle, Washington 98109, USA
    Urology 72:474-80. 2008
  4. ncbi request reprint Association of body mass index with response and survival in men with metastatic prostate cancer: Southwest Oncology Group trials 8894 and 9916
    R Bruce Montgomery
    University of Washington and Southwest Oncology Group Statistical Center, Seattle, Washington, USA
    J Urol 178:1946-51; discussion 1951. 2007
  5. ncbi request reprint Diethylstilbestrol and docetaxel: a Phase II study of tubulin active agents in patients with metastatic, androgen-independent prostate cancer
    R Bruce Montgomery
    Department of Medicine, Veterans Affairs Puget Sound Health Care System VAPSHCS, and University of Washington School of Medicine, Seattle, WA 98108, USA
    Cancer 110:996-1002. 2007
  6. ncbi request reprint Estrogen effects on tubulin expression and taxane mediated cytotoxicity in prostate cancer cells
    R Bruce Montgomery
    Department of Medicine, University of Washington, Seattle, 98108, USA
    Prostate 65:141-50. 2005
  7. ncbi request reprint Endogenous anti-HER2 antibodies block HER2 phosphorylation and signaling through extracellular signal-regulated kinase
    R Bruce Montgomery
    Division of Oncology, Department of Medicine, VA Puget Sound HCS University of Washington, Seattle, WA 98108, USA
    Cancer Res 65:650-6. 2005
  8. ncbi request reprint Antagonistic and agonistic effects of quinazoline tyrosine kinase inhibitors on mutant EGF receptor function
    R Bruce Montgomery
    Department of Medicine, Division of Oncology, University of Washington and VA Puget Sound HCS, Seattle, WA 98108, USA
    Int J Cancer 101:111-7. 2002
  9. ncbi request reprint An antibody targeting the type I insulin-like growth factor receptor enhances the castration-induced response in androgen-dependent prostate cancer
    Stephen R Plymate
    Department of Medicine, University of Washington, Seattle, Washington 98104, USA
    Clin Cancer Res 13:6429-39. 2007
  10. pmc Targeted androgen pathway suppression in localized prostate cancer: a pilot study
    Elahe A Mostaghel
    Elahe A Mostaghel, Rachel Hunter Merrill, and Roman Gulati, Fred Hutchinson Cancer Research Center Elahe A Mostaghel, Peter S Nelson, Paul Lange, Daniel W Lin, William Ellis, Robert Vessella, and Bruce Montgomery, University of Washington Brett Marck, Alvin M Matsumoto, and Lawrence D True, Veterans Affairs Puget Sound Health Care System, Seattle, WA Mary Ellen Taplin and Philip Kantoff, Dana Farber Cancer Institute, Harvard Medical School Steven Balk, Beth Israel Deaconess Medical Center, Boston, MA and Daniel Tamae and Trevor Penning, University of Pennsylvania, Philadelphia, PA
    J Clin Oncol 32:229-37. 2014

Research Grants

  1. PHASE I TRIAL OF A PEPTIDE VACCINE AGAINST EGFRVIII
    Bruce Montgomery; Fiscal Year: 1999
  2. PHASE I TRIAL OF A PEPTIDE VACCINE AGAINST EGFRVIII
    Bruce Montgomery; Fiscal Year: 2003
  3. PHASE I TRIAL OF A PEPTIDE VACCINE AGAINST EGFRVIII
    Bruce Montgomery; Fiscal Year: 2004
  4. PHASE I TRIAL OF A PEPTIDE VACCINE AGAINST EGFRVIII
    Bruce Montgomery; Fiscal Year: 2005

Collaborators

Detail Information

Publications36

  1. ncbi request reprint Expression of oncogenic epidermal growth factor receptor family kinases induces paclitaxel resistance and alters beta-tubulin isotype expression
    R B Montgomery
    Department of Medicine and Oncology, Veterans Affairs Puget Sound Health Care System, University of Washington, Seattle, Washington 98108, USA
    J Biol Chem 275:17358-63. 2000
    ..This effect on tubulin expression may modulate drug resistance in human malignancies that express these oncogenes...
  2. pmc Estradiol suppresses tissue androgens and prostate cancer growth in castration resistant prostate cancer
    Bruce Montgomery
    Department of Medicine, University of Washington School of Medicine, 1959 NE Pacific St, Seattle, WA, USA
    BMC Cancer 10:244. 2010
    ..We hypothesize that estrogen inhibits CRPC in anorchid animals by suppressing tumoral androgens, an effect independent of the estrogen receptor...
  3. doi request reprint Veterans Affairs Cooperative Studies Program study 553: Chemotherapy after prostatectomy, a phase III randomized study of prostatectomy versus prostatectomy with adjuvant docetaxel for patients with high-risk, localized prostate cancer
    Bruce Montgomery
    Veterans Affairs Puget Sound Health Care System and University of Washington, Seattle, Washington 98109, USA
    Urology 72:474-80. 2008
  4. ncbi request reprint Association of body mass index with response and survival in men with metastatic prostate cancer: Southwest Oncology Group trials 8894 and 9916
    R Bruce Montgomery
    University of Washington and Southwest Oncology Group Statistical Center, Seattle, Washington, USA
    J Urol 178:1946-51; discussion 1951. 2007
    ..We evaluated the effect of body mass index on prostate specific antigen response, and progression-free and overall survival in men with androgen dependent or androgen independent metastatic prostate cancer...
  5. ncbi request reprint Diethylstilbestrol and docetaxel: a Phase II study of tubulin active agents in patients with metastatic, androgen-independent prostate cancer
    R Bruce Montgomery
    Department of Medicine, Veterans Affairs Puget Sound Health Care System VAPSHCS, and University of Washington School of Medicine, Seattle, WA 98108, USA
    Cancer 110:996-1002. 2007
    ..The addition of diethylstilbestrol to docetaxel modified tubulin composition and improved the response of prostate cancer to chemotherapy in preclinical models. An attempt was made to recapitulate the observations in a clinical trial...
  6. ncbi request reprint Estrogen effects on tubulin expression and taxane mediated cytotoxicity in prostate cancer cells
    R Bruce Montgomery
    Department of Medicine, University of Washington, Seattle, 98108, USA
    Prostate 65:141-50. 2005
    ....
  7. ncbi request reprint Endogenous anti-HER2 antibodies block HER2 phosphorylation and signaling through extracellular signal-regulated kinase
    R Bruce Montgomery
    Division of Oncology, Department of Medicine, VA Puget Sound HCS University of Washington, Seattle, WA 98108, USA
    Cancer Res 65:650-6. 2005
    ..Endogenous anti-HER2 antibodies can effectively suppress HER2 kinase activity and downstream signaling to inhibit the transformed phenotype of HER2-expressing tumor cells...
  8. ncbi request reprint Antagonistic and agonistic effects of quinazoline tyrosine kinase inhibitors on mutant EGF receptor function
    R Bruce Montgomery
    Department of Medicine, Division of Oncology, University of Washington and VA Puget Sound HCS, Seattle, WA 98108, USA
    Int J Cancer 101:111-7. 2002
    ....
  9. ncbi request reprint An antibody targeting the type I insulin-like growth factor receptor enhances the castration-induced response in androgen-dependent prostate cancer
    Stephen R Plymate
    Department of Medicine, University of Washington, Seattle, Washington 98104, USA
    Clin Cancer Res 13:6429-39. 2007
    ....
  10. pmc Targeted androgen pathway suppression in localized prostate cancer: a pilot study
    Elahe A Mostaghel
    Elahe A Mostaghel, Rachel Hunter Merrill, and Roman Gulati, Fred Hutchinson Cancer Research Center Elahe A Mostaghel, Peter S Nelson, Paul Lange, Daniel W Lin, William Ellis, Robert Vessella, and Bruce Montgomery, University of Washington Brett Marck, Alvin M Matsumoto, and Lawrence D True, Veterans Affairs Puget Sound Health Care System, Seattle, WA Mary Ellen Taplin and Philip Kantoff, Dana Farber Cancer Institute, Harvard Medical School Steven Balk, Beth Israel Deaconess Medical Center, Boston, MA and Daniel Tamae and Trevor Penning, University of Pennsylvania, Philadelphia, PA
    J Clin Oncol 32:229-37. 2014
    ..The failure to completely ablate tissue androgens may limit suppression of PCa growth. We evaluated combinations of CYP17A and 5-α-reductase inhibitors for reducing prostate androgen levels, AR signaling, and PCa volumes...
  11. ncbi request reprint Effects of the herbal extract PC-SPES on microtubule dynamics and paclitaxel-mediated prostate tumor growth inhibition
    Michael J Bonham
    Division of Human Biology, Fred Hutchinson Cancer Research Center, Seattle, WA 98109 1024, USA
    J Natl Cancer Inst 94:1641-7. 2002
    ..We sought to identify PC-SPES-induced changes in gene expression, specifically in those genes encoding cytoskeletal proteins that could be associated with PC-SPES-induced cytoxicity...
  12. ncbi request reprint Characterization of chemical constituents in Scutellaria baicalensis with antiandrogenic and growth-inhibitory activities toward prostate carcinoma
    Michael Bonham
    Divisions of Human Biology and Clinical Research, Fred Hutchinson Cancer Research Center and Department of Medicine and Oncology, Veterans Affairs Puget Sound Health Care System, University of Washington, Seattle, Washington, USA
    Clin Cancer Res 11:3905-14. 2005
    ..Due to the difficulties encountered when evaluating the efficacy of complex natural products, we sought to identify active chemical constituents within Scutellaria and determine their mechanisms of action...
  13. ncbi request reprint Response of the insulin-like growth factor (IGF) system to IGF-IR inhibition and androgen deprivation in a neoadjuvant prostate cancer trial: effects of obesity and androgen deprivation
    James P Dean
    Human Biology Division, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109, USA
    J Clin Endocrinol Metab 98:E820-8. 2013
    ....
  14. pmc Resistance to CYP17A1 inhibition with abiraterone in castration-resistant prostate cancer: induction of steroidogenesis and androgen receptor splice variants
    Elahe A Mostaghel
    Division of Clinical Research and Human Biology, Fred Hutchinson Cancer Research Center Department of Medicine, University of Washington, Seattle, Washington, USA
    Clin Cancer Res 17:5913-25. 2011
    ..The effectiveness of abiraterone in reducing tumor androgens is not known, nor have mechanisms contributing to abiraterone resistance been established...
  15. pmc Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth
    R Bruce Montgomery
    Department of Medicine, University of Washington School of Medicine, Weattle, WA, USA
    Cancer Res 68:4447-54. 2008
    ..Maximal therapeutic efficacy in the treatment of castration-resistant prostate cancer will require novel agents capable of inhibiting intracrine steroidogenic pathways within the prostate tumor microenvironment...
  16. ncbi request reprint Characterization of osteoblastic and osteolytic proteins in prostate cancer bone metastases
    Sandy R Larson
    Department of Urology, University of Washington, Seattle, Washington 98195, USA
    Prostate 73:932-40. 2013
    ..We determined whether previously identified and/or novel proteins were associated with the osteoblastic or osteolytic response in clinical specimens of PCa bone metastases...
  17. ncbi request reprint Molecular effects of the herbal compound PC-SPES: identification of activity pathways in prostate carcinoma
    Michael Bonham
    Divisions of Human Biology, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109, USA
    Cancer Res 62:3920-4. 2002
    ....
  18. pmc MEK4 function, genistein treatment, and invasion of human prostate cancer cells
    Li Xu
    Department of Medicine, Robert H Lurie Cancer Center and Center for Drug Discovery and Chemical Biology of Northwestern University, Chicago, IL60610, USA
    J Natl Cancer Inst 101:1141-55. 2009
    ..We investigated the target for genistein in prostate cancer cells...
  19. pmc Expression of SLCO transport genes in castration-resistant prostate cancer and impact of genetic variation in SLCO1B3 and SLCO2B1 on prostate cancer outcomes
    Jonathan L Wright
    Department of Urology, University of Washington, Seattle, WA, USA
    Cancer Epidemiol Biomarkers Prev 20:619-27. 2011
    ....
  20. doi request reprint Testosterone regulates tight junction proteins and influences prostatic autoimmune responses
    Jing Meng
    Divisions of Human Biology and Clinical Research, Fred Hutchinson Cancer Research Center, D4 100, 1100 Fairview Ave N, Seattle, WA 98109 1024, USA
    Horm Cancer 2:145-56. 2011
    ....
  21. ncbi request reprint Unconventional therapy for prostate cancer: good, bad or questionable?
    Peter S Nelson
    Division of Human Biology, Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue, Seattle, Washington 98105, USA
    Nat Rev Cancer 3:845-58. 2003
  22. pmc Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletion
    William P Harris
    Fred Hutchinson Cancer Research Center and the University of Washington School of Medicine, Seattle, WA 98195, USA
    Nat Clin Pract Urol 6:76-85. 2009
    ....
  23. ncbi request reprint Combined in vivo effect of A12, a type 1 insulin-like growth factor receptor antibody, and docetaxel against prostate cancer tumors
    Jennifer D Wu
    Department of Medicine, University of Washington, Seattle, WA 98104, USA
    Clin Cancer Res 12:6153-60. 2006
    ..Based on these data, we investigated the combined in vivo effect of A12 and docetaxel on human androgen-independent and osseous prostate tumor growth...
  24. ncbi request reprint Tumor lysis syndrome in a patient with metastatic, androgen independent prostate cancer
    Jonathan L Wright
    Department of Urology, University of Washington, WA, USA
    Int J Urol 12:1012-3. 2005
    ..It is rarely described in patients with solid tumors. We report a case of TLS in a patient with metastatic adenocarcinoma of the prostate after treatment with paclitaxel chemotherapy...
  25. pmc Treatment and survival outcomes in young men diagnosed with prostate cancer: a Population-based Cohort Study
    Daniel W Lin
    Department of Urology, Virginia Puget Sound Health Care System, University of Washington, Northwest Prostate Cancer Specialized Program of Research Excellence, Seattle, Washington, USA
    Cancer 115:2863-71. 2009
    ..In this study, the authors examined the association between age at diagnosis and grade, stage, treatment, and survival outcomes in men who were diagnosed during the era of prostate-specific antigen testing...
  26. ncbi request reprint The development of a telemedical cancer center within the Veterans Affairs Health Care System: a report of preliminary clinical results
    Kevin G Billingsley
    Department of Surgery, VA Puget Sound Health Care System and the University of Washington Seattle, Washington 98108, USA
    Telemed J E Health 8:123-30. 2002
    ..Preliminary clinical results demonstrate the program is feasible and it improves access to multidisciplinary cancer care. Potential benefits include improved referral coordination and minimization of patient travel and treatment delays...
  27. pmc Castration-resistant prostate cancer: targeting androgen metabolic pathways in recurrent disease
    Elahe A Mostaghel
    Division of Human Biology, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
    Urol Oncol 27:251-7. 2009
    ..Targeting these metabolic enzymes either individually or using combinations of agents to inhibit testicular, adrenal, and intracrine sources may provide enhanced clinical responses in the setting of both localized and metastatic disease...
  28. ncbi request reprint Cell type-specific analyses for identifying prostate cancer biomarkers
    Peter S Nelson
    Fred Hutchinson Cancer Research Center, Division of Human Biology, 1100 Fairview Avenue North, Seattle, WA 98109 1024, USA
    Curr Urol Rep 7:57-63. 2006
    ..This review describes approaches that use cell type-specific analysis methods to identify cancer-associated features with the potential of distinguishing individuals with cancer of the prostate...
  29. ncbi request reprint Phase I and initial phase II results from a trial investigating weekly docetaxel and carboplatin given neoadjuvantly and then concurrently with concomitant boost radiotherapy for locally advanced squamous cell carcinoma of the head and neck
    David L Schwartz
    Radiation Oncology Service, Seattle VA Puget Sound Health Care System, Seattle, Washington, USA
    Cancer 103:2534-43. 2005
    ..The current Phase I/II study assessed induction docetaxel/carboplatin given weekly for 4 weeks, followed by weekly docetaxel/carboplatin and concomitant boost radiotherapy (CB-XRT) for locally advanced head and neck squamous cell carcinoma...
  30. pmc Single cell transcriptomic analysis of prostate cancer cells
    Christopher J Welty
    Department of Urology, University of Washington, Seattle, WA, USA
    BMC Mol Biol 14:6. 2013
    ..A high stringency threshold, a mean Alexa Fluor® 3 signal intensity above 300, was used for gene detection. Relative expression levels were validated for select genes using real-time PCR (RT-qPCR)...
  31. pmc Molecular pathways: targeting resistance in the androgen receptor for therapeutic benefit
    Elahe A Mostaghel
    Authors Affiliations Division of Clinical Research, Fred Hutchinson Cancer Research Center and Department of Medicine, University of Washington, Seattle, Washington
    Clin Cancer Res 20:791-8. 2014
    ....
  32. pmc Glucocorticoids and prostate cancer treatment: friend or foe?
    Bruce Montgomery
    Department of Medicine, University of Washington, Seattle, Washington, USA
    Asian J Androl 16:354-8. 2014
    ....
  33. ncbi request reprint The prognostic significance of Gleason pattern 5 in prostate cancer patients treated with Pd-103 brachytherapy
    Hiroki Mitsuyama
    Department of Radiation Oncology, Puget Sound Health Care System, Department of Veterans Affairs, Seattle, WA 98108 1597, USA
    Am J Clin Oncol 30:597-600. 2007
    ..To determine the effect of high-grade prostate cancer (Gleason pattern 5) on the prognosis of patients treated with Pd-103 brachytherapy...
  34. pmc Impact of circulating cholesterol levels on growth and intratumoral androgen concentration of prostate tumors
    Elahe A Mostaghel
    Division of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America
    PLoS ONE 7:e30062. 2012
    ....
  35. ncbi request reprint The increasing role of CAM in prostate cancer
    Gabrielle Zecha
    University of Washington, Seattle, USA
    JAAPA 17:37-40, 43-4. 2004
  36. ncbi request reprint The basic biochemistry and molecular events of hormone therapy
    Elahe A Mostaghel
    Division of Medical Oncology, Department of Medicine, University of Washington, Seattle, WA 98109, USA
    Curr Urol Rep 8:224-32. 2007
    ....

Research Grants4

  1. PHASE I TRIAL OF A PEPTIDE VACCINE AGAINST EGFRVIII
    Bruce Montgomery; Fiscal Year: 1999
    ..To characterize effects of human anti-EGFRvIII antibodies on EGFRvIII signaling. 4. To determine the level of EGFR specific T cell response after immunization with EGFRvIII peptide. ..
  2. PHASE I TRIAL OF A PEPTIDE VACCINE AGAINST EGFRVIII
    Bruce Montgomery; Fiscal Year: 2003
    ..To characterize effects of human anti-EGFRvIII antibodies on EGFRvIII signaling. 4. To determine the level of EGFR specific T cell response after immunization with EGFRvIII peptide. ..
  3. PHASE I TRIAL OF A PEPTIDE VACCINE AGAINST EGFRVIII
    Bruce Montgomery; Fiscal Year: 2004
    ..To characterize effects of human anti-EGFRvIII antibodies on EGFRvIII signaling. 4. To determine the level of EGFR specific T cell response after immunization with EGFRvIII peptide. ..
  4. PHASE I TRIAL OF A PEPTIDE VACCINE AGAINST EGFRVIII
    Bruce Montgomery; Fiscal Year: 2005
    ..To characterize effects of human anti-EGFRvIII antibodies on EGFRvIII signaling. 4. To determine the level of EGFR specific T cell response after immunization with EGFRvIII peptide. ..